Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,775 total articles

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Pharmaceuticals announced its participation in the 2026 American Academy of Neurology Annual Meeting with presentations including late-breaking Phase 3 X-TOLE2 study results and long-term 48-month data of azetukalner for focal onset seizures. The company will also showcase real-world clinical data on epilepsy treatment challenges and progress…

Himax Technologies, Inc. Schedules First Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 at 8:00 AM EDT

Himax Technologies, Inc. Schedules First Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 at 8:00 AM EDT

Himax Technologies, a global leader in display driver ICs and semiconductor products, announced its first quarter 2026 financial results conference call to be held on May 7, 2026. The company will discuss its latest financial performance and business outlook in a live webcast and teleconference accessible worldwide. Himax is known for its innovatio…

LPL Welcomes Emerald Legacy Advisors

LPL Welcomes Emerald Legacy Advisors

LPL Financial announced that Emerald Legacy Advisors, managing approximately $140 million in assets, have joined LPL’s broker-dealer and Registered Investment Advisor platform. Emerald Legacy, known for its personalized financial planning and intergenerational client focus, chose LPL for its independence, scale, and access to robust investment solu…

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

Outlook Therapeutics submitted a formal dispute resolution request to the FDA following a Complete Response Letter on its Biologics License Application for ONS-5010/LYTENAVA™, an ophthalmic bevacizumab formulation for wet age-related macular degeneration (AMD). The FDA accepted the request and scheduled a meeting. The company emphasizes sufficient …

Cloudastructure to Participate in “Powering the AI Revolution” Virtual Conference Presented by Maxim Group LLC on Tuesday, April 7th at 9:00 a.m. EDT

Cloudastructure to Participate in “Powering the AI Revolution” Virtual Conference Presented by Maxim Group LLC on Tuesday, April 7th at 9:00 a.m. EDT

Cloudastructure announced that its CEO and CFO will participate in the 'Powering the AI Revolution' virtual conference hosted by Maxim Group, focusing on infrastructure needs driven by generative AI. The event will cover challenges such as land acquisition, capital deployment, and construction sequencing to meet increasing demand for AI infrastruct…

OFA Group Strengthens Balance Sheet and Long-Term Earnings Profile Through Strategic IP Ownership Realignment

OFA Group Strengthens Balance Sheet and Long-Term Earnings Profile Through Strategic IP Ownership Realignment

OFA Group has finalized a strategic intellectual property ownership restructuring for its QIKBIM platform, acquiring 50% co-ownership and full operational control. The transaction reclassifies $12 million in development expenditures as capitalized intangible assets, enhancing the balance sheet, improving earnings stability, and boosting cash flow v…

Roundtable CEO James Heckman Details NASDAQ Strategy, Long-Term Focus, Capitalization Structure, and Lock-Up

Roundtable CEO James Heckman Details NASDAQ Strategy, Long-Term Focus, Capitalization Structure, and Lock-Up

Following shareholder approval of the merger between Roundtable and RYVYL Inc., CEO James Heckman detailed the strategic equity capitalization framework designed to satisfy Nasdaq liquidity requirements while aligning management and investors for long-term growth. The combined entity will have approximately 13.5 million shares outstanding, with 85%…

PennantPark Floating Rate Capital Ltd. Schedules Earnings Release of Second Fiscal Quarter 2026 Results

PennantPark Floating Rate Capital Ltd. Schedules Earnings Release of Second Fiscal Quarter 2026 Results

PennantPark Floating Rate Capital Ltd. will release its second fiscal quarter 2026 financial results on May 7, 2026, followed by a conference call on May 8. The company invests primarily in middle-market U.S. private companies through floating rate senior secured loans and some equity investments and is managed by PennantPark Investment Advisers, a…

Jet.AI Inc. Announces Reverse Stock Split

Jet.AI Inc. Announces Reverse Stock Split

Jet.AI Inc. announced a 1-for-200 reverse stock split effective April 8, 2026, to comply with Nasdaq's minimum bid price requirements and increase available shares for future issuance. The company's ticker symbol JTAI will remain unchanged on the Nasdaq Capital Market. The split adjusts issued and outstanding shares from approximately 129 million t…

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Curanex Pharmaceuticals highlights a patient case study involving Phyto-N treatment for cancer cachexia associated with pancreatic neuroendocrine tumor. The case showed significant symptomatic and biomarker improvements, suggesting Phyto-N’s potential to address an unmet need in supportive care for cancer patients experiencing severe physical decli…